Eva Asp

Title: **Innovator Spotlight: Eva Asp**

Introduction

Eva Asp, a prominent inventor based in Newton, MA, is known for her contributions to the field of biotechnology. With a remarkable portfolio of four patents, she has made significant strides in the understanding and treatment of amyloid-related diseases.

Latest Patents

One of her latest inventions is the development of the General Amyloid Interaction Motif (GAIM). This invention relates to variants of the GAIM derived from the bacteriophage gene 3 protein (g3p), along with fusion proteins. These GAIM variants are designed to be partially or fully deimmunized, demonstrating improved binding and specificity toward various amyloid proteins. This work not only enhances amyloid remodeling but also inhibits amyloid aggregation. Additionally, the invention encompasses nucleic acids, vectors, host cells, and methods for creating these GAIM variants, which can be crucial for developing pharmaceutical therapies aimed at increasing bacteriophage infectivity. Furthermore, her research includes methods for detecting amyloid aggregates and diagnosing diseases associated with misfolded or aggregated amyloid proteins.

Another notable patent focuses on polypeptides that comprise modified portions of the filamentous bacteriophage gene 3 protein (g3p). These polypeptides have been engineered to lack a glycosylation signal, thereby retaining their ability to bind and disaggregate amyloid while being less immunogenic in vivo. This innovation has applications in the treatment and prevention of diseases related to amyloid aggregation.

Career Highlights

Eva has played significant roles in various innovative companies, including Amyl Therapeutics and Proclara Biosciences. Through her work, she has made vital contributions to the advancement of biotechnology and the therapeutic landscape surrounding amyloid-related diseases.

Collaborations

Throughout her career, Eva has collaborated with prominent professionals in the field, including Rajaraman Krishnan and Ming Proschitsky. These partnerships have enriched her research and facilitated the development of groundbreaking inventions.

Conclusion

Eva Asp's innovative work continues to pave the way for advancements in the diagnosis and treatment of amyloid diseases. With her impressive patent portfolio and collaborative spirit, she remains a key figure in the biotechnology industry, driving forward the frontiers of scientific discovery.